TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CStone Pharmaceuticals ( (HK:2616) ) has shared an announcement.
CStone Pharmaceuticals announced that its CEO, Dr. Jianxin Yang, along with senior management, has increased their shareholding in the company by purchasing 1,000,000 shares, with Dr. Yang acquiring 700,000 shares. This move underscores their confidence in the company’s long-term investment value and growth prospects, as well as their commitment to its future business success. The board views this increase in shareholding as a sign of strong belief in the company’s ability to maintain steady operations and achieve rapid growth, which could positively impact stakeholder confidence.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals, established in late 2015 and listed on the Hong Kong Stock Exchange, is a biopharmaceutical company focused on developing therapies for oncology, autoimmune/inflammation, and other key disease areas. The company has launched four innovative drugs and secured approvals for 16 new drug applications across nine indications. CStone’s pipeline includes 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines. The management team possesses comprehensive experience across the drug development spectrum.
Average Trading Volume: 22,904,614
Technical Sentiment Signal: Buy
Current Market Cap: HK$10B
For an in-depth examination of 2616 stock, go to TipRanks’ Overview page.